Insole on Morton's Neuroma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03511677 |
Recruitment Status :
Completed
First Posted : April 30, 2018
Last Update Posted : April 30, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Objective: The aim of the present study was to assess the effectiveness of insole with metatarsal support on pain in patients with Morton's neuroma and the impact of this insole on function, load distribution in the plantar region, gait variables, quality of life and satisfaction with insole use.
Methods: A randomized, controlled, double-blind, clinical trial with intent-to-treat analysis. Seventy-two patients with Morton's neuroma were randomly allocated into a study group and control group. One week following the baseline evaluation, the study group received insole with metatarsal support made of ethyl vinyl acetate and the control group received a flat insole of the same material, color and density. The groups were evaluated after 6, 12 and 24 weeks of insole use. The following assessment parameters employed: pain when walking and at rest (END); quality of life (SF-36); foot function (FFI and FHSQ); six-minute walk test (6MWT) and foot pressure analysis using the AM Cube FootWalk Pro program.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Morton Neuroma | Device: Insole Device: Placebo Insole | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 72 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Outcomes Assessor) |
Masking Description: | Placebo insole |
Primary Purpose: | Treatment |
Official Title: | Effectiveness of Insole on Morton's Neuroma |
Actual Study Start Date : | June 1, 2015 |
Actual Primary Completion Date : | March 31, 2018 |
Actual Study Completion Date : | March 31, 2018 |
Arm | Intervention/treatment |
---|---|
Experimental: Intervention Group
Customized insole with metatarsal support
|
Device: Insole
Customized insole |
Placebo Comparator: Control Group
Placebo flat insole
|
Device: Placebo Insole
Placebo flat insole |
- Change in pain [ Time Frame: Baseline, after 6, 12 and 24 weeks ]Measured by visual analogue scale from 0 cm to 10 cm
- Change in function and foot health [ Time Frame: Baseline, after 6, 12 and 24 weeks ]Measured by Foot function index questionnaire
- Change in function, foot healt and quality of life [ Time Frame: Baseline, after 6, 12 and 24 weeks ]Measured by Foot Health Status questionnaire
- Change in function [ Time Frame: Baseline, after 6, 12 and 24 weeks ]Measured by the distance in the six minute walking test
- Quality of life [ Time Frame: Baseline, after 6, 12 and 24 weeks ]Measured by the Short Form -36 questionnaire

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient with clinical and radiological diagnosis (magnetic resonance or ultrasound) of Morton's neuroma.
- Pain in the foot with VAS between 3-8 cm to walk.
- Over 18 years.
- No distinction of sex
- Agree to participate of the study and sign the informed consent form.
Exclusion Criteria:
- Other symptomatic musculoskeletal diseases in MMII.
- Symptomatic diseases of the central and peripheral nervous system.
- Diabetes Mellitus.
- Rigid deformities on foot.
- Use of insoles in the last three months.
- Physiotherapy in the last three months.
- Infiltrations on foot and ankles in the last three months.
- Previous or expected surgery in the next twelve months.
- Allergy to the material of the insole.
- Mental deficiency.
- Geographic inaccessibility .- Use of corticosteroids or NSAIDs in the last month
Responsible Party: | Hilda Alcantara Veiga de Oliveira, PT, MsC, Federal University of São Paulo |
ClinicalTrials.gov Identifier: | NCT03511677 |
Other Study ID Numbers: |
20634013.9.0000.5505. |
First Posted: | April 30, 2018 Key Record Dates |
Last Update Posted: | April 30, 2018 |
Last Verified: | April 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Insole Morton Neuroma Pain Function |
Neuroma Morton Neuroma Nerve Sheath Neoplasms Neoplasms, Nerve Tissue Neoplasms by Histologic Type Neoplasms Metatarsalgia Foot Diseases |
Musculoskeletal Diseases Joint Diseases Neuralgia Peripheral Nervous System Diseases Neuromuscular Diseases Nervous System Diseases Pain Neurologic Manifestations |